Literature DB >> 15361712

Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer.

Lisa Kurlender1, George M Yousef, Nader Memari, John-Desmond Robb, Iacovos P Michael, Carla Borgoño, Dionyssios Katsaros, Carsten Stephan, Klaus Jung, Eleftherios P Diamandis.   

Abstract

The presence of more than one mRNA form is common among kallikrein genes. We identified an mRNA transcript of the human kallikrein gene 5 (KLK5), denoted KLK5 splice variant 1 (KLK5-SV1). This variant has a different 5'-splice site, but encodes the same protein as the classical KLK5 transcript. RT-PCR analysis of this variant transcript expression in 29 human tissues indicated highest expression in the cervix, salivary gland, kidney, mammary gland, and skin. Comparative analysis of the expression levels of KLK5-SV1, another splice variant named KLK5 splice variant 2 (KLK5-SV2), and the classical KLK5 form showed that out of all three mRNA transcripts, the classical form is predominantly expressed (found in more tissues and at higher expression levels) followed by KLK5-SV1. KLK5-SV1 is expressed at high levels in ovarian, pancreatic, breast and prostate cancer cell lines. KLK5-SV1 was also found to be expressed in 9/10 ovarian cancer tissues, but it was not found in one normal ovarian tissue tested. Hormonal regulation experiments suggest that KLK5-SV1 is regulated by steroid hormones in the BT-474 breast cancer cell line. Furthermore, this variant had significantly higher expression in normal prostate tissues compared to their matched cancer tissue counterparts. KLK5-SV1 may have clinical utility in various malignancies and should be further explored as a potential new biomarker for prostate and ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361712     DOI: 10.1159/000079147

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  3 in total

Review 1.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

2.  A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.

Authors:  Sang Wook Lee; Kazuo Hosokawa; Soyoun Kim; Ok Chan Jeong; Hans Lilja; Thomas Laurell; Mizuo Maeda
Journal:  Sensors (Basel)       Date:  2015-05-22       Impact factor: 3.576

Review 3.  Kallikreins as biomarkers for prostate cancer.

Authors:  Sung Kyu Hong
Journal:  Biomed Res Int       Date:  2014-04-07       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.